CLINICAL ROLE -
Once-Daily COPD Triple Therapy Gets FDA Approval
Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) is a single-inhaler triple therapy for the long-term, maintenance treatment of patients with chronic obstructive pulmonary disease.
Read More
Newly Approved Osteoporosis Drug Carries Cancer Risk
Tymlos, an injection that treats postmenopausal women with osteoporosis, may incrase the risk of osteosarcoma.
Monthly PCSK9 Inhibitor Injection Gets FDA Approval
Cholesterol-lowering drug approved in once-monthly 300 mg dosing option.